中国医药科学2016，Vol.6Issue(3)：95-97,154,4.
去甲氧柔红霉素与柔红霉素治疗初治AML的疗效分析
Analysis of clinical effect of idarubicin and daunorubicin in initial treatment of acute myeloid leukemia
初晓丽 1金锷 1王瑞姝 1田宏1
作者信息
- 1. 沈阳市第四人民医院肿瘤血液科，辽宁沈阳110000
- 折叠
摘要
Abstract
Objective To compare and analyze curative effect and adverse reactions of idarubicin(IDr)combined with cytosine arabinoside and DA(daunorubicin combined with cytosine arabinoside)in treatment of AML(acute myeloid leukemia)during the first course. Methods 89 patients with initial diagnosis of non-promyelocytic AML in department of tumor and hematology who were hospitalized in Shenyang Fourth People's Hospital from January 2010 to January 2015 were retrospectively analyzed.All the patients were divided into two groups according to their chemotherapy regimens(IA or DA).Effective rate of treatment adverse reactions of two groups were analyzed and evaluated. Results The total effective rate of first course and complete relief rate of the IA group were 94.44% and 55.56%respectively.The total effective rate of first course and complete relief rate of the DA group were 79.25%and 32.08% respectively.The differences between two groups had statistical significance(P < 0.05).Infection rate of IA group was high.Other adverse reactions of two groups had significant difference. Conclusion Compared with DA regimen,complete relief rate in the first course of IA regimen in initial treatment of AML patients was higher. But IA has longer bone marrow suppression time and higher infection rate. Incidence of adverse reactions of IA and DA program has no great difference.关键词
去甲氧柔红霉素/柔红霉素/阿糖胞苷/急性白血病Key words
Idarubicin/Daunorubicin/Cytosine arabinoside/Acute myeloid leukemia分类
医药卫生引用本文复制引用
初晓丽,金锷,王瑞姝,田宏..去甲氧柔红霉素与柔红霉素治疗初治AML的疗效分析[J].中国医药科学,2016,6(3):95-97,154,4.
